MAIA

MAIA Biotechnology, Inc.

NYSE AmericanUSDEQUITY DELAYED

1.35

▼ 0.03 (2.11%)

MARKET · —

Price

Open

1.42

Prev close

1.38

Day high

1.41

Day low

1.35

Volume

379.74K

Market cap

—

P/E (TTM)

—

52W range

0.87 – 3.19

Trailing performance

Price return · vs SPY

Returnvs SPY

-0.71% +0.7%

+8.59% +4.9%

+8.59% +5.5%

-33.17% -44.2%

YTD

-9.15% -21.4%

-12.03% -32.0%

-29.08% -103.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

1.38

-2.32% from price

SMA 20

1.35

+3.08% from price

SMA 50

1.37

+1.65% from price

SMA 100

1.34

+0.60% from price

SMA 200

1.47

-5.18% from price

EMA 12

1.38

-1.82% from price

EMA 26

1.36

-1.03% from price

EMA 50

1.36

-1.03% from price

RSI (14)

53.7

Neutral

MACD (12,26,9)

0.01

Hist 0.00

ATR (14)

0.05

3.83% of price

Realised vol 30D

48.8%

Annualised

Bollinger upper

1.48

20, 2σ

Bollinger lower

1.22

20, 2σ

50 / 200 cross

Death

1.37 vs 1.47

Trend bias

Below 200

-5.18%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.79

More volatile than market

Correlation to SPY

0.26

Largely independent

Realised vol 30D

48.8%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-59.3%

Peak to trough

Max drawdown 5Y

-89.4%

Peak to trough

ATR 14

0.05

3.83% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 1.35

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

MAIA · links out to the publisher

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) GlobeNewswire · 5d ago MAIA Biotechnology Says Ateganosine Shows 90.5% Disease Control Rate in Phase 2 Expansion Trial MT Newswires · 45d ago MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial GlobeNewswire · 45d ago MAIA Biotechnology Completes Part C International Enrollment for Phase 2 Ateganosine Trial MT Newswires · 58d ago MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer GlobeNewswire · 58d ago MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University GlobeNewswire · 65d ago MAIA Biotechnology Activates Second US Site for Phase 2 Trial of Lung Cancer Treatment MT Newswires · 73d ago MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial GlobeNewswire · 73d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.